Concomitant antipsychotic prescribing in US outpatient settings

Research in Social and Administrative Pharmacy

Volumn 5, Issue 3, 2009, Pages 234-241

  Aparasu, Rajender R ^a   Jano, Elda ^a   Bhatara, Vinod ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Antipsychotic; Atypical; Concomitant; Polypharmacy; Psychosis

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BIPOLAR DISORDER; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG UTILIZATION; ECONOMICS; FEMALE; HEALTH CARE QUALITY; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; OUTPATIENT; PRESCRIPTION; PSYCHOSIS; SOCIOECONOMICS; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADULT; AGED; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHOTIC DISORDERS; QUALITY ASSURANCE, HEALTH CARE; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

EID: 69649096978     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2008.08.005     Document Type: Article

References (37)

1. Tapp A., Kennedy A., Kilzieh N., Rosengren K., and Wood A. Combination antipsychotic therapy for the treatment of schizophrenia. Essent Psychopharmacol 6 1 (2004) 1-11 Review
2. Stahl S.M. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret?. J Clin Psychiatr 60 (1999) 425-426
3. Freudenreich O., and Goff D.C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106 5 (2002 Nov) 323-330
4. Miller A.L., and Craig C.S. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 28 1 (2002) 105-109
5. Ananth J., Parameswaran S., and Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des 10 18 (2004) 2231-2238
6. Stahl S.M., and Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11 3 (2004) 313-327
7. Stahl S.M., and Grady M.M. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 57 1 (2006) 127-129
8. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia (1997), American Psychiatric Association, Washington, DC
9. Miller A.L., Crismon M.L., Rush A.J., Chiles J., Kashner T.M., Toprac M., Carmody T., et al. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 30 (2004) 627-647
10. Joint commission. Candidate hospital-based inpatient psychiatric measure set to be available for testing in 2007. Available at:. http://www.jointcommission.org/NR/rdonlyres/71BAD5DA-CB9B-444C-9911-EDEB 2F074740/0/HBIPSFORWEB_RevisionsCM.pdf Accessed February 6, 2008 Date Retrieved
11. Schumacher J.E., Makela E.H., and Griffin H.R. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37 7-8 (2003) 951-955
12. McCue R.E., Waheed R., and Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatr 64 9 (2003) 984-989
13. Chakos M.H., Glick I.D., Miller A.L., et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57 (2006) 1094-1101
14. Faries D., Ascher-Svanum H., Zhu B., Correll C., and Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5 1 (2005) 26
15. Weissman E.M. Antipsychotic prescribing practices in the veterans healthcare administration-New York metropolitan region. Schizophr Bull 28 (2002) 31-42
16. Kogut S.J., Yam F., and Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm 11 1 (2005) 17-24
17. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., and Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54 1 (2003) 55-59
18. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., and Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65 10 (2004) 1377-1388
19. Clark R.E., Bartels S.J., Mellman T.A., and Peacock W.J. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28 1 (2002) 75-84
20. Kreyenbuhl J., Valenstein M., McCarthy J.F., Ganoczy D., and Blow F.C. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 84 1 (2006) 90-99
21. Biancosino B., Barbui C., Marmai L., Dona S., and Grassi L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 20 6 (2005) 305-309
22. Botts S., Hines H., and Littrell R. Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatr Serv 54 8 (2003) 1086
23. National Center for Health Statistics. National Ambulatory Medical Care Survey. Available at:. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS / Accessed February 6, 2008
24. National Center for Health Statistics. National Hospital Ambulatory Medical Care Survey. Available at:. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHAMC S/ Accessed February 6, 2008
25. Tenney J.B., White K.L., Williamson J.W., and April. National ambulatory medical care survey: background and methodology: United States, 1967-72. Vital Health Stat 2 61 (1974)
26. McCaig L.F., and McLemore T. Plan and operation of the National hospital ambulatory medical care survey. Vital Health Stat 1 34 (1994)
27. US Department of Health and Human Services, Centers for Disease Control and Prevention, and Health Care Financing Administration. Clinical modification. 9th revision. International Classification of Diseases. 6th ed (2004)
28. Koch H., and Cambell W. The collection and processing of drug information. National center for health statistics. Vital Health Stat 2 90 (1982)
29. Van Brunt D.L., Gibson P.J., Ramsey J.L., and Obenchain R. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. Med Gen Med 5 (2003) 16
30. Aparasu R., Bhatara V., and Gupta S.U.S. National trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry 17 (2005) 147-152
31. SAS-STAT. SAS Institute, Inc. Changes and enhancements, Release 8.0. Cary, NC; 2001.
32. Hing E., Gousen S., Shimizu I., et al. Guide to using masked design variables to estimate standard errors in public use files of the National ambulatory medical care survey and the National hospital ambulatory medical care survey. Inquiry 40 (2003) 401-415
33. Olfson M., Blanco C., Liu L., et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63 (2006) 679-685
34. Lerner V., Libov I., Kotler M., and Strous R.D. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 28 1 (2004) 89-98
35. Lieberman J.A. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatr 68 2 (2007) e04
36. Aparasu R.R., and Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin 23 1 (2007) 49-56
37. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., and Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2 (2004) 13